Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
The Future of the NDMM: Comparing Emergent Regimens and Understanding Unmet Needs
Dr. Costa and Dr. Schmidt consider promising emergent treatment options and current unmet needs in the NDMM treatment landscape.
Optimizing Consolidation and Maintenance Therapy in the NDMM Treatment Landscape
Experienced clinicians share their perspectives on maintenance therapy for patients with NDMM.
A Practical Approach to Treatment Selection for Patients with NDMM
Subject-matter experts share their perspectives on treatment selection for patients with NDMM.
Key Data and Outcomes from the GRIFFIN Trial
A summary of updates from the GRIFFIN trial evaluating D-RVd in clinically relevant NDMM patient subgroups.
Clinical Insights from the Results of the MASTER Trial
Thoughtful discussion centered around recently presented updates to the MASTER trial.
An Introduction to NDMM: Treatment Options and Patient Risk Stratification
Luciano Costa, MD, PhD and Timothy Schmidt, MD introduce treatment regimen options and risk stratification for patients with transplant-eligible NDMM.
Unmet Needs and Future Directions in Care in Multiple Myeloma
Closing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.
What is the Role of CAR T-Cell Therapy in R/R MM?
Expert perspectives on the advent of CAR T-cell therapy in relapsed/refractory multiple myeloma, and how its role may integrate with bispecific antibody therapy.
R/R MM: Optimizing Treatment Sequencing With Bispecific Antibodies
Before closing out their discussion on bispecific antibodies in relapsed/refractory multiple myeloma, key opinion leaders consider optimal sequencing of these agents.
Non–BCMA-Targeting Bispecific Antibodies in R/R MM
A brief review of non–BCMA-targeted bispecific antibodies under investigation in patients with relapsed/refractory multiple myeloma.
BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Expert perspectives on recent clinical data on BCMA-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.
Selecting Treatment Regimens for Multiple Myeloma at First Relapse
Turning to the last module, expert panelists discuss the treatment armamentarium for patients experiencing early relapse in multiple myeloma.
Choosing the Right Treatment for Patients With Transplant Ineligible MM
Patient and disease factors that help to select best first-line therapy in the setting of transplant-ineligible multiple myeloma.
Approaching Induction Therapy for Patients With Transplant-Ineligible MM
Switching their focus to transplant-ineligible multiple myeloma, panelists review available triplet therapy regimens for induction therapy.
Selecting The Appropriate Treatment in Transplant-Eligible Newly Diagnosed MM
A brief discussion how to select the appropriate treatment strategy in transplant-eligible newly diagnosed myeloma and whether there is a role for minimal residual disease in assessing response and treatment duration.
Should Every Patient With Newly Diagnosed MM Receive a Transplant?
In light of recent clinical trial data, key opinion leaders reflect on the appropriate selection of transplant for patients with newly diagnosed multiple myeloma.
The Evolving Treatment Landscape of Transplant-Eligible Newly Diagnosed Multiple Myeloma
Opening discussion on the management of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider the role of quadruplet therapy and transplant in this setting.
2 Commerce Drive Cranbury, NJ 08512